Genmab — Maj 2015
-
Nordea om genmabs P/E "Du betaler over 100 kroner for
1 krones overskud i år. Biotekselskaber synes ofte meget dyrt prissat, da der er en
forventning om høj indtjening i fremtiden. Genmab er ingen undtagelse. Hvis
Daratumumab mod knoglemarvskræft bliver en salgssucces, som vi ser god sandsynlighed
for, falder prissætningen også drastisk. Vi ser således god værdi i biotekaktien,
hvor den årlige kræftkonference, der starter i morgen, ses som en potentiel
kursdriver." -
Bulder, hvad sker der så her den 31.5 "Assessing clinical response in multiple myeloma (MM) patients treated with
monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex
assay (DIRA) to distinguish malignant M-protein from therapeutic antibody.
(Abstract 8590) C. McCudden, A. Axel, D. Slaets, S. Frans, J. Bald, J. M.
Schecter, T. Ahmadi, T. Plesner, K. Sasser"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind